Variables One MTX prescription Two or more MTX prescriptions ≤50 years 679 (15%) 3,849 (85%)
<0.001 51–60 years 648 (15%) 3,672 (85%) 61–70 years 631 (13%) 4,223 (87%) >70 years 950 (19%) 4,053 (81%) Men 784 (15%) 4,447 (85%)
0.089 Women 2,161 (16%) 11,350 (84%) No prior use of prednisolone/prednisone 1,053 (15%) 6,206 (85%)
0.002 Prior use of prednisolone/prednisone 1,853 (16%) 9,591 (84%) No AMI 2,741 (15%) 15,188 (85%)
<0.001 AMI 165 (21%) 609 (79%) No cerebrovascular disease 2,697 (15%) 15,015 (85%)
<0.001 Cerebrovascular disease 209 (21%) 782 (79%) No dementia 2,884 (15%) 15,739 (85%)
0.003 Dementia 22 (27%) 58 (73%) No complications to T1D 2,860 (15%) 15,660 (85%)
<0.001 Complications to T1D 46 (25%) 137 (75%) No complications to T2D 2,834 (15%) 15,590 (85%)
<0.001 Complications to T2D 72 (26%) 207 (74%) No T1D 2,830 (15%) 15,551 (85%)
<0.001 T1D 76 (24%) 246 (76%) No T2D 2,751 (15%) 15,218 (85%)
<0.001 T2D 155 (21%) 579 (79%) No hemiplegia 2,898 (15%) 15,775 (85%)
0.092 Hemiplegia 8 (27%) 22 (73%) No heart failure 2,735 (15%) 15,281 (85%)
<0.001 Heart failure 171 (25%) 516 (75%) No peripheral vascular disease 2,741 (15%) 15,268 (85%)
<0.001 Peripheral vascular disease 165 (24%) 529 (76%) No chronic lung disease 2,553 (15%) 14,588 (85%)
<0.001 Chronic lung disease 353 (23%) 1,209 (77%) No leukemia 2,901 (15%) 15,773 (85%)
0.800 Leukemia 5 (17%) 24 (83%) No lymphoma 2,886 (15%) 15,718 (85%)
0.199 Lymphoma 20 (20%) 79 (80%) No metastases 2,880 (15%) 15,725 (85%)
0.003 Metastases 26 (26%) 72 (74%) No mild liver disease 2,852 (15%) 15,647 (85%)
<0.001 Mild liver disease 54 (26%) 150 (74%) No moderate to severe liver disease 2,903 (15%) 15,771 (85%)
0.440 Moderate to severe liver disease 3 (10%) 26 (90%) No kidney disease 2,816 (15%) 15,560 (85%)
<0.001 Kidney disease 90 (27%) 237 (73%) No cancer 2,813 (15%) 15,414 (85%)
0.015 Cancer 93 (19%) 383 (81%) No ulcer 2,664 (15%) 14,832 (85%)
<0.001 Ulcer 242 (20%) 965 (80%)
